期刊文献+

2型糖尿病患者血清脂联素水平的变化 被引量:3

原文传递
导出
摘要 持续微量白蛋白尿是2型糖尿病发生糖尿病肾病(DN)的标志。美国糖尿病学会(ADA)推荐随意时点的尿白蛋白/肌酐比率(UACR)作为尿白蛋白排泄异常的指标,用于DN的筛查和诊断。脂联素(APN)是脂肪组织分泌的一种细胞因子,与肥胖和2型糖尿病密切相关。我们前期的研究表明,APN起延缓糖尿病视网膜病变发生发展的作用。为进一步揭示APN与糖尿病微血管病变之间的关系,本研究以2型糖尿病患者的UACR水平进行分组,分析血清APN水平变化及其与UACR、血脂、血糖及体质量指数(BMI)等因素之间的关系,探讨APN在2型糖尿病。肾病发生发展过程中的作用。
出处 《中华肾脏病杂志》 CAS CSCD 北大核心 2009年第5期394-395,共2页 Chinese Journal of Nephrology
  • 相关文献

参考文献7

  • 1American Diabetes Association. Standards of medical care in diabetes-2007. Diabetes Care, 2007, 30 Suppl 1: S4-S41.
  • 2张合珍,李兴.肿瘤坏死因子-α、脂联素与糖尿病视网膜病变的关系[J].中华眼底病杂志,2007,23(4):293-294. 被引量:4
  • 3Koshimura J, Fujita H, Narita T, et al. Urinary adiponectin excretion is increased in patients with overt diabetic nephropathy. Biochem Biophys Res Commun, 2004, 316: 165-169.
  • 4Maeda K, Okubo K, Shimomura I, et al. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (adipose most abundant gene transcript 1) . Biochem Biophys Res Commun, 1996, 221: 286-289.
  • 5Yamauchi T, Kamom J, ho Y, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature, 2003, 423: 762-769.
  • 6Yamauchi T, Kamom J, Waki H, et al. Globular adiponectin protected ob /ob mice from diabetes and apoE-deficient mice from atherosclerosis. J Biol Chem, 2003, 278: 2461- 2468.
  • 7李艳波,韩君勇,李为民.斯伐他汀对糖尿病肾病大鼠肾小球系膜细胞p38信号通路的影响[J].中华肾脏病杂志,2007,23(2):91-94. 被引量:10

二级参考文献21

  • 1李艳波,邓华聪,郑丹,李呼伦.P38信号通路对人脐静脉内皮细胞单核细胞趋化蛋白-1表达的影响[J].中华糖尿病杂志(1006-6187),2004,12(4):287-289. 被引量:8
  • 2葛倩,邓华聪,刘金波.脂联素对血管内皮功能的影响[J].中华内分泌代谢杂志,2006,22(1):15-18. 被引量:42
  • 3Tuo QH, Wang C, Yan FX, et al. MAPK pathway mediates the protective effects of onychin on oxidative stress-induced apoptosis in ECV304 endothelial cells, Life Sci, 2004, 76:487-497.
  • 4Takahashi M, Hayashi K, Yoshida K, et al. Epiregulin as a major autocrine/paracrine factor released from ERK-and p38MAPK-activated vascular smooth muscle cells,Circulation, 2003, 108: 2524-2529.
  • 5Chen S, Hong SW, Iglesias-de la Cruz MC, et al. The key role of the transforming growth factorvbeta system in the pathogenesis of diabetic nephropathy, Ren Fail, 2001, 23:471-481.
  • 6Kim SI, Han DC, Lee HB. Levastatin inhibits transforming growth factor-batal 1 expression in diabetic rat glomeruli and cultured rat mesangial cells. J Am Soc Nephrol, 2000, 11:80-87.
  • 7Makita Z, Vlassara H, Cerami A, et al. Immunochemical detection of advanced glycosylation end products in vivo. J Boil Chem, 1992, 267: 5133-5138.
  • 8Okada S, Shikata K, Matsuda M, et al. Intercellular adhesion molecule-1-deficient mice are resistant against renal injury after induction of diabetes. Diabetes, 2003, 52: 2586-2593.
  • 9Kim NH, Kim KB, Kim DL, et al. Plasma and urinary vascular endothelial growth factor and diabetic nephropathy in type 2 diabetes mellitus. Diabet Med, 2004, 21: 545-551.
  • 10Blanc A, Pandey NR, Srivastava AK. Synchronous activation of ERK1/2, p38MAPK and PKB/Akt signaling by H2O2 invascular smooth muscle cells: potential involvement in vascular disease (review). Int J Mol Med, 2003, 11: 229-234.

共引文献12

同被引文献37

  • 1黎磊石,刘志红.糖尿病肾病的治疗[J].中华老年多器官疾病杂志,2002,1(3):171-173. 被引量:14
  • 2侯凡凡,谢迪.慢性肾脏病的治疗——合理降压控制尿蛋白逆转肾小球硬化[J].中国实用内科杂志,2007,27(13):1010-1012. 被引量:29
  • 3刘志文,周智广,陈小燕,刘玉华,宁洁,周卫东,唐炜立,冯琼,何霞,庞翠军,彭健.四种干预方案对新诊2型糖尿病亚临床动脉粥样硬化的影响[J].中国糖尿病杂志,2007,15(6):344-347. 被引量:5
  • 4Kim KS, Koh JM, Song KH, et al. Incidence of overt pro teinuria and coronary artery disease in patients with type 2 diabetes mellitus., the role of microalbuminuria and retinopathy[J]. Diabetes Res Clin Praet, 2004, 65 (2) : 159-165.
  • 5Ochodnicky P, Henning RH, van Dokkum RP, et al. Microalbuminuria and endothelial dysfunction:emerging targets for primary prevention of end-- organ damage [J]. J CardiovascPharmaeol, 2006, 47 (suppl2):S151-S162.
  • 6Zhiqiang W, Wendy EH. Albuminuria as a marker of the risk of developing type 2 diabetes in non-diabetic Aboriginal Australians [J]. Int J Epidemiol, 2006, 35 (5) : 1331-1335.
  • 7Stehouwer CD, Nauta J J, Zeldenrust GC, et al. Urinary albumin excretion, cardiovascular disease, and endothelial dys function in non-insulin-dependent diabetes mellitus [J]. Lancet 1992, 340 (8815): 319-323.
  • 8UKPDS Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKDS 33) [J]. Lancet, 1998, 352 (9131): 837-853.
  • 9Shichiri M, Kishikawa H, Ohkubo Y, et al. Long-term re suits of the Kumamoto study on optimal diabetes control in type 2 diabetic patients [J]. Diabetes Care, 2000, 23 (Suppl 2): B21-29.
  • 10HolmanRR, Paul SK, Bethel MA, etal. 10-yearfollow-upof intensive glucose control in type 2 diabetes [J]. N Engl J Med, 2008, 359 (15): 1577-1589.

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部